Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $10.4 million.

  • Cytokinetics' Gains from Investment Securities was N/A to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2024, which is 11.55% down from last year.
  • As of FY2024, Cytokinetics' Gains from Investment Securities stood at $10.4 million, which was down 11.55% from $11.8 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Gains from Investment Securities peaked at $11.8 million during FY2023, and registered a low of $8.5 million during FY2020.
  • Its 3-year average for Gains from Investment Securities is $11.1 million, with a median of $11.0 million in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first grew by 17.28% in 2022, then fell by 11.55% in 2024.
  • Over the past 5 years, Cytokinetics' Gains from Investment Securities (Yearly) stood at $8.5 million in 2020, then rose by 10.24% to $9.4 million in 2021, then rose by 17.28% to $11.0 million in 2022, then grew by 7.17% to $11.8 million in 2023, then fell by 11.55% to $10.4 million in 2024.